Industry
Biotechnology
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
April 08, 2024 | 12:16 pm
Portfolio Pulse from Benzinga Insights
March 28, 2024 | 8:20 pm
Portfolio Pulse from dijoy@benzinga.com
March 28, 2024 | 8:20 pm
Portfolio Pulse from Benzinga Insights
March 28, 2024 | 9:24 am
Portfolio Pulse from Benzinga Insights
March 27, 2024 | 6:01 pm
Portfolio Pulse from Benzinga Newsdesk
January 22, 2024 | 5:09 pm
Portfolio Pulse from Erica Kollmann
January 16, 2024 | 5:41 pm
Portfolio Pulse from Benzinga Newsdesk
January 16, 2024 | 1:40 pm
Portfolio Pulse from Benzinga Newsdesk
November 15, 2023 | 2:02 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.